PHP
GYRE icon

Parkman Healthcare Partners’s Gyre Therapeutics GYRE Stock Holding History

Parkman Healthcare Partners’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17,793
Closed -$548K – 87
2021
Q3 		$548K Sell
17,793
-34,667
-66% -$1.14M 0.14% 71
2021
Q2 		$1.7M Buy
52,460
+244
+0.5% +$8.37K 0.37% 64
2021
Q1 		$1.97M Buy
52,216
+26,995
+107% +$1.23M 0.46% 55
2020
Q4 		$1.19M Sell
25,221
-2,576
-9% -$112K 0.31% 72
2020
Q3 		$896K Sell
27,797
-901
-3% -$35.3K 0.24% 73
2020
Q2 		$1.26M Hold
28,698
– – 0.36% 66
2020
Q1 		$941K Buy
+28,698
New +$1.32M 0.44% 54

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Parkman Healthcare Partners's GYRE Position: Q4 2021 in Review

Parkman Healthcare Partners sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 17,793 shares — an estimated $548K sold.

Parkman Healthcare Partners first reported a position in GYRE in Q1 2020 and held it in 7 quarters. The position peaked at $1.97M in Q1 2021. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

  • Parkman Healthcare Partners reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Parkman Healthcare Partners sold 17,793 Gyre Therapeutics shares in Q4 2021, an estimated $548K.
  • Parkman Healthcare Partners first reported a position in Gyre Therapeutics in Q1 2020 and held it in 7 quarters.
  • Parkman Healthcare Partners's Gyre Therapeutics position peaked at $1.97M in Q1 2021.
  • 51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on Parkman Healthcare Partners's 13F filing for Q4 2021, filed 11 Feb 2022.